Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.
about
Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiationA modified human ELISPOT assay to detect specific responses to primary tumor cell targetsWhy do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytesGraft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.From the study of tumor cell immunogenicity to the generation of antitumor cytotoxic cells in non-Hodgkin's lymphomas.Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.Inverse regulation of the ADAM-family members, decysin and MADDAM/ADAM19 during monocyte differentiation.Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.The leukocyte semaphorin CD100 is expressed in most T-cell, but few B-cell, non-Hodgkin's lymphomas.Characterization of tumor-infiltrating T lymphocytes in B-cell lymphomas of mucosa-associated lymphoid tissue.Induction of antigen-specific T cell anergy: An early event in the course of tumor progressionHuman non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses.In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunityImmunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.Identification of a costimulatory molecule rapidly induced by CD40L as CD44H.A human minor histocompatibility antigen resulting from differential expression due to a gene deletionB lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement.The role of B7 family molecules in hematologic malignancyCD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cellsChronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses.Low natural killer (NK) cell counts in peripheral blood adversely affect clinical outcome of patients with follicular lymphoma.CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma.Adenovirus-mediated LIGHT gene modification in murine B-cell lymphoma elicits a potent antitumor effectTuning of CD40-CD154 interactions in human B-lymphocyte activation: a broad array of in vitro models for a complex in vivo situation.CD40-activated B cells as antigen-presenting cells: the final sprint toward clinical application.Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies.Salmonella enterica serovar Typhimurium immunotherapy for B-cell lymphoma induces broad anti-tumour immunity with therapeutic effect.Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus.Immortalization of Epstein-Barr virus-negative human B lymphocytes with minimal chromosomal instability.A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2.Histological and immunological parameters to predict treatment outcome of Helicobacter pylori eradication in low-grade gastric MALT lymphoma.Enhancement of cALL immunogenicity by co-culture with a CD154 expressing 293 cell line.Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.High dose therapy and autologous stem cell transplantation in follicular non-Hodgkin's lymphoma.
P2860
Q24314914-2477779F-4914-4810-8829-2F821671DF28Q24800412-608FE9F4-6682-473E-A64B-183B370F05DAQ33536297-4F0D38BF-81FF-4B7A-81A7-9C601C5A88CDQ33791998-DDC4D262-9A0E-48D0-8E67-C445322C5F53Q33857800-0A9477D3-1B20-4AE7-8B58-476D6D8EBE5FQ33919954-C0EE776F-CD30-4D8F-BD07-55FC09BF1383Q33929813-D3A99E65-ABF7-4661-907F-A844EF495711Q34124707-B08AF527-955E-4CAB-9027-3B82A6F6CE66Q34278407-998ADAAD-2E0E-4AA3-A391-5AF634A0EFC8Q34734310-04F17ABD-679A-4D71-8824-4BC2B2A0962CQ34773444-350EC9C0-9768-4361-BFC8-EECE518BA31EQ35399334-5ED521BB-0BB9-472C-B1FC-A59C721CA566Q35753111-A78CAFF8-0360-4633-8DDD-DD5658CCE19BQ35764108-BDC8B906-42D6-4F7A-A83F-DC9C5EA2A8B3Q35798927-AD3DCF90-C30F-4AE9-A30D-EA75B2A9515FQ35834633-8D0FD9DA-00EA-4A2C-875B-8E8E18025567Q35848586-FF66F676-7829-4D47-81CD-B023C71192A5Q35848688-815C3892-C811-4782-8D71-E32654FA8787Q36367256-F9782FBD-45B4-4ACD-AF2E-33A8BAC21C81Q36370375-A821D36F-DD33-4120-894B-AC6E2BC220DAQ36400397-55FD8091-8626-46B8-A2CF-6F1AD75C3C5FQ36584814-649CCCBA-EBA7-4C69-81D7-1733BDF6290DQ36601966-BB85223B-566E-442D-8FBF-66C30D3E9947Q36712736-CDE2E228-5279-4083-9536-4AED8574985FQ37116255-472E9DFD-6FF6-4266-B282-0FDD8F948986Q37254746-15DC933D-D6E8-46D9-8262-847B3CC371A9Q37375643-A93710F5-56EA-418D-A07A-2EFE705467CDQ37685586-F0DD7858-F43B-442E-B3F3-806094C5ABCEQ37729679-DC7214B1-72F2-4B27-927D-3B3B6C853B15Q37828473-60E01900-A640-43F1-813D-120F42A23D61Q38113268-06EA0C12-90F3-4DC8-BA7D-F266DC348816Q38372054-C012E087-562F-4F8F-AE2D-4A6D88EFE2DCQ38994432-45F86626-0CBC-4465-B725-1B510C53C820Q39275435-C3B6AEDC-3781-4812-908B-A219382E6AFFQ40220428-02AA6980-25A3-437E-A38E-DBDB6DD79B19Q40602227-4730AB00-C999-44FC-91DB-55B27DCD4575Q40720388-6B5A92F5-829D-45AD-BC6A-3C2178A090C9Q40790005-177C48C3-6BCD-4AA4-A21B-17B30F079F76Q40795774-CE4A9D5C-7D41-45D8-89F8-91B68D566B11Q40865563-A4919B6E-C2D4-4421-9123-9B5B107EA296
P2860
Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.
description
1995 nî lūn-bûn
@nan
1995 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Follicular lymphomas can be in ...... ve their tumor immunogenicity.
@ast
Follicular lymphomas can be in ...... ve their tumor immunogenicity.
@en
type
label
Follicular lymphomas can be in ...... ve their tumor immunogenicity.
@ast
Follicular lymphomas can be in ...... ve their tumor immunogenicity.
@en
prefLabel
Follicular lymphomas can be in ...... ve their tumor immunogenicity.
@ast
Follicular lymphomas can be in ...... ve their tumor immunogenicity.
@en
P2093
P2860
P356
P1476
Follicular lymphomas can be in ...... ve their tumor immunogenicity.
@en
P2093
A A Cardoso
G J Freeman
G S Pinkus
J G Gribben
L M Nadler
M J Seamon
P2860
P304
P356
10.1073/PNAS.92.18.8200
P407
P577
1995-08-01T00:00:00Z